Today announced the initiation of a Stage 3 clinical trial.

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in sufferers with myelofibrosis Cell Therapeutics, Inc. today announced the initiation of a Stage 3 clinical trial, known as PERSIST-2, that will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in sufferers with myelofibrosis whose platelet counts are significantly less than or add up to 100,000 per microliter . The trial is expected to enroll up to 300 patients in North America, Europe, New and Australia Zealand within 12 to 14 months common info . In 2013 October, CTI reached agreement with the U.S. Food and Medication Administration on a particular Protocol Evaluation for the PERSIST-2 trial, which really is a written contract between CTI and the FDA concerning the planned style, endpoints and statistical evaluation approach of the trial to be used in support of a potential New Medication Software, or NDA, submission.